SOUTH SAN FRANCISCO, Calif., Sept. 23, 2024 /PRNewswire/ — IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced positive interim Phase 2 clinical trial data for darovasertib in neoadjuvant uveal melanoma (UM) and a successful FDA Type C meeting on registrational trial design for regulatory approval in neoadjuvant UM.
Health Professionals
Oncologist explains new treatment for advanced melanoma called tumor-infiltrating lymphocyte therapy
Melanoma is a dangerous form of skin cancer that has the potential to spread to other parts of the body.
Tumour-specific antibodies able to detect melanoma in its earliest stages, new study shows
(Thursday, 26 September 2024, Amsterdam, Netherlands) Innovative research has unveiled promising advancements in melanoma detection, which could significantly enhance diagnosis and prognosis by identifying the disease at its earliest, most treatable stages.
New biomarker profiling enhances early detection of melanoma
Innovative research has unveiled promising advancements in melanoma detection, which could significantly enhance diagnosis and prognosis by identifying the disease at its earliest, most treatable stages.